Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Crinetics (CRNX) PT Raised to $70 at Morgan Stanley
May 22, 2024 3:24 PM EDTMorgan Stanley analyst Jeffrey Hung raised the price target on Crinetics (NASDAQ: CRNX) to $70.00 (from $50.00) while maintaining a Overweight rating.
The analyst comments "ENDO abstracts for Crinetics were released ahead of schedule including initial atumelnant Phase 2 data which we find competitive (see... More
